A- A A+

USA:. HS Expands Access to Treatment for Opioid Use Disorder 

The U.S. Department of Health and Human Services is publishing Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder*, to expand access to medication-assisted treatment (MAT) by exempting physicians from certain certification requirements needed to prescribe buprenorphine for opioid use disorder (OUD) treatment. (HHS, USA, Januar 2021)

https://www.hhs.gov/sites/default/files/mat-physician-practice-guidelines.pdf

Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. 

Jones CM, Guy GP Jr, Board A.

Drug Alcohol Depend. 2021 Jan 6;219:108486. doi: 10.1016/j.drugalcdep.2020.108486. Epub ahead of print. PMID: 33421802; PMCID: PMC7787058.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787058/

Experten-Web-Konferenz. Suchtbehandlung in Covid-Zeiten: der disruptive Zwang zur Innovation

JATROS Neurologie & Psychiatrie 6/20, p. 27-29

19_J_Neuro_Kon_ÖGABS Experten-Web-Konferenz_Barth final

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada. 

Morin KA, Acharya S, Eibl JK, Marsh DC. 

Int J Drug Policy. 2020 Dec 23;90:103088. doi: 10.1016/j.drugpo.2020.103088. Epub ahead of print. PMID: 33385974.

https://pubmed.ncbi.nlm.nih.gov/33385974/

Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre. 

Gómez-Ramiro M, Fico G, Anmella G, Vázquez M, Sagué-Vilavella M, Hidalgo-Mazzei D, Pacchiarotti I, Garriga M, Murru A, Parellada E, Vieta E. 

J Affect Disord. 2020 Dec 27;282:26-32. doi: 10.1016/j.jad.2020.12.057. Epub ahead of print. PMID: 33387743; PMCID: PMC7765763.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765763/

COVID-19 Pandemic and People Who Use Opioids in India: Opportunities and Evolutions.

Parmar A, Rina K, Padhy SK. 

Indian J Psychol Med. 2020 Nov 5;42(6):566-568. doi: 10.1177/0253717620965882. PMID: 33354084; PMCID: PMC7735229.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735229/

Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts. 

Yang J, Landrum MB, Zhou L, Busch AB. 

Gen Hosp Psychiatry. 2020 Nov-Dec;67:100-106. doi: 10.1016/j.genhosppsych.2020.09.004. Epub 2020 Oct 12. PMID: 33091782; PMCID: PMC7550185.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550185/

The Impact of COVID-19 Pandemic on the Castile and Leon Addiction Treatment Network: A Real-Word Experience. 

Roncero C, Vicente-Hernández B, Casado-Espada NM, Aguilar L, Gamonal-Limcaoco S, Garzón MA, Martínez-González F, Llanes-Álvarez C, Martínez R, Franco-Martín M, Álvarez-Navares A. 

Front Psychiatry. 2020 Nov 25;11:575755. doi: 10.3389/fpsyt.2020.575755. PMID: 33324254; PMCID: PMC7723843.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723843/

Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19. 

Livingston NA, Ameral V, Banducci AN, Weisberg RB. 

J Subst Abuse Treat. 2020 Dec 3:108222. doi: 10.1016/j.jsat.2020.108222. Epub ahead of print. PMID: 33303255.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30479-7/fulltext

Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. 

Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. 

J Subst Abuse Treat. 2020 Dec 3:108219. doi: 10.1016/j.jsat.2020.108219. Epub ahead of print. PMID: 33353790.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30476-1/fulltext

Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. 

Dunn KE, Brooner RK, Stoller KB. 

J Subst Abuse Treat. 2021 Feb;121:108197. doi: 10.1016/j.jsat.2020.108197. Epub 2020 Nov 24. PMID: 33357606.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33357606/

COVID-19 and treating incarcerated populations for opioid use disorder. 

Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA. 

J Subst Abuse Treat. 2020 Dec 2:108216. doi: 10.1016/j.jsat.2020.108216. Epub ahead of print. PMID: 33288348; PMCID: PMC7708799.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708799/

The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19. 

Hughto JMW, Peterson L, Perry NS, Donoyan A, Mimiaga MJ, Nelson KM, Pantalone DW. 

J Subst Abuse Treat. 2021 Jan;120:108163. doi: 10.1016/j.jsat.2020.108163. Epub 2020 Oct 9. PMID: 33298301; PMCID: PMC7545305.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545305/

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. 

Arunogiri S, Lintzeris N. 

J Subst Abuse Treat. 2020 Dec 3:108221. doi: 10.1016/j.jsat.2020.108221. Epub ahead of print. PMID: 33303254; PMCID: PMC7711199.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711199/

Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. 

Duncan A, Sanders N, Schiff M, Winkelman TNA.

J Subst Abuse Treat. 2021 Feb;121:108161. doi: 10.1016/j.jsat.2020.108161. Epub 2020 Oct 8. PMID: 33371945; PMCID: PMC7543710.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543710/

Developments in Drug Addiction During COVID-19 - An Austrian Perspective Based on a Clinical Sample. 

Fuchs-Leitner I, Yazdi K, Gerstgrasser NW, Rosenleitner J. 

Front Psychiatry. 2020 Nov 27;11:602033. doi: 10.3389/fpsyt.2020.602033. PMID: 33329157; PMCID: PMC7728611.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728611/

Kanada. Impacts of the COVID-19 Pandemic on Substance Use Treatment Capacity in Canada

Key Findings

There was a substantial decrease in the availability and capacity of substance use treatment and harm reduction services in the early phase of the pandemic (March–June) due to closures and restrictions on the number of clients allowed at clinics and inpatient facilities. 

This decrease, along with other factors, led to many clients returning to or engaging in higher-risk substance use, and growing wait times for services.

Access to substance use treatment services and supports has not returned to pre-pandemic levels. Delivery of care for substance use treatment shifted rapidly to virtual platforms, which had some positive impact on treatment access.

Availability of virtual care is not equitably distributed,and it cannot completely replace the need for in-person treatment options.

(Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances, Dezember 2020)

https://www.ccsa.ca/sites/default/files/2020-12/CCSA-COVID-19-Impacts-Pandemic-Substance-Use-Treatment-Capacity-Canada-2020-en.pdf

USA. Saving Lives From Overdose During a Pandemic

John Hopkins Bloomberg School of Public Health, USA, December 2020

https://americanhealth.jhu.edu/sites/default/files/website-media/resources/saving-lives-from-overdose.pdf

Telehealth sustains patient engagement in OUD treatment during COVID-19. 

Langabeer JR 2nd, Yatsco A, Champagne-Langabeer T. 

J Subst Abuse Treat. 2020 Nov 24:108215. doi: 10.1016/j.jsat.2020.108215. Epub ahead of print. PMID: 33248863; PMCID: PMC7685137.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685137/

Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic. 

Cance JD, Doyle E. 

JAMA. 2020;324(23):2442–2444. doi:10.1001/jama.2020.22154

https://jamanetwork.com/journals/jama/fullarticle/2774040

Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. 

Wenzel K, Fishman M. 

J Subst Abuse Treat. 2021 Jan;120:108149. doi: 10.1016/j.jsat.2020.108149. Epub 2020 Sep 24. PMID: 33303086.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30406-2/fulltext

Applying the lessons of COVID-19 response to Canada's worsening opioid epidemic. 

Norton A, Kerr T. 

EClinicalMedicine. 2020 Dec;29:100633. doi: 10.1016/j.eclinm.2020.100633. Epub 2020 Nov 20. PMID: 33235987; PMCID: PMC7677043.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677043/

Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. 

Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. 

J Subst Abuse Treat. 2020 Oct 10:108164. doi: 10.1016/j.jsat.2020.108164. Epub ahead of print. PMID: 33191004.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30421-9/fulltext

Integration of a contraception clinic into an opioid treatment setting to improve contraception knowledge, accessibility and uptake: a pilot study. 

Day CA, White B, Reid SE, Fowler M, Black KI. 

Aust N Z J Public Health. 2020 Oct;44(5):360-362. doi: 10.1111/1753-6405.13025. Epub 2020 Aug 31. PMID: 32865845.

https://onlinelibrary.wiley.com/doi/10.1111/1753-6405.13025

USA. Coronapandemie führt in USA zu Zunahme der Zahl der Drogentoten

Washington – Die Coronapandemie hat in den USA zu einer Zunahme der Zahl der Drogentoten geführt. In der zwölfmonatigen Auswertungsperiode bis zum Monat Mai habe es mehr als 81.000 Drogentote ge­geben, teilte die Gesundheitsbehörde CDC gestern mit.

Das sei die höchste Zahl, die jemals für einen zwölfmonatigen Zeitabschnitt festgestellt worden sei. (aerzteblatt.de, 18.12.2020)

https://www.aerzteblatt.de/nachrichten/119550/Coronapandemie-fuehrt-in-USA-zu-Zunahme-der-Zahl-der-Drogentoten

COVID-19 pandemic and addiction: Current problems in Iran. 

Pirnia B, Dezhakam H, Pirnia K, Malekanmehr P, Soleimani AA, Zahiroddin A, Eslami MR, Sadeghi P. 

Asian J Psychiatr. 2020 Dec;54:102313. doi: 10.1016/j.ajp.2020.102313. Epub 2020 Jul 23. PMID: 32738562; PMCID: PMC7377711.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377711/

The SARS-Cov-2 threat in Cracolândia, an open-air drug use scene in Brazil. 

Arcadepani FB, Tardelli VS, Fidalgo TM. 

Int J Drug Policy. 2020 Sep;83:102835. doi: 10.1016/j.drugpo.2020.102835. Epub 2020 Jul 2. PMID: 32690405; PMCID: PMC7330576.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330576/

Acceptance of e-consult for Substance Use Disorders during the COVID 19 pandemic: A study from India. 

Sahu P, Mathur A, Ganesh A, Nair S, Chand P, Murthy P. 

Asian J Psychiatr. 2020 Dec;54:102451. doi: 10.1016/j.ajp.2020.102451. Epub 2020 Oct 15. PMID: 33271730; PMCID: PMC7557176.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557176/

Adolescent substance use: Challenges and opportunities related to COVID-19. 

Sarvey D, Welsh JW. 

J Subst Abuse Treat. 2020 Nov 24:108212. doi: 10.1016/j.jsat.2020.108212. Epub ahead of print. PMID: 33272731.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(20)30469-4/fulltext

A delicate compromise: Striking a balance between public safety measures and the psychosocial needs of staff and clients in residential substance use disorder treatment amid COVID-19. 

Herrera A. 

J Subst Abuse Treat. 2020 Nov 24:108208. doi: 10.1016/j.jsat.2020.108208. Epub ahead of print. PMID: 33272732; PMCID: PMC7683954.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683954/